Dubai PR Network, Online Press Release from Dubai and Middle East
 
Healthcare(Healthcare & Medicine)
Filter PR by
  
Cleveland Clinic Launches First-of-its Kind Preventive Breast Cancer Vaccine Study
 

Novel clinical trial based on research from Cleveland Clinic’s Lerner Research Institute
  
 
Wednesday, 27 October, 2021:   Researchers from a top American hospital, Cleveland Clinic, have opened a novel study for a vaccine aimed at eventually preventing triple-negative breast cancer, the most aggressive and lethal form of the disease. 
 
This phase I trial is designed to determine the maximum tolerated dose of the vaccine in patients with early-stage triple-negative breast cancer and to characterize and optimize the body’s immune response. The U.S. Food and Drug Administration recently approved an investigational new drug application for the vaccine, which permits Cleveland Clinic and partner Anixa Biosciences, Inc. (ANIX:NASDAQ) to start the study. 
 
“We are hopeful that this research will lead to more advanced trials to determine the effectiveness of the vaccine against this highly aggressive type of breast cancer,” said G. Thomas Budd, M.D., of Cleveland Clinic’s Taussig Cancer Institute and principal investigator of the study. “Long term, we are hoping that this can be a true preventive vaccine that would be administered to healthy women to prevent them from developing triple-negative breast cancer, the form of breast cancer for which we have the least effective treatments.” 
 
There is a great need for improved treatments for triple-negative breast cancer, which does not have biological characteristics that typically respond to hormonal or targeted therapies. Despite representing only about 12-15% of all breast cancers, triple-negative breast cancer accounts for a disproportionately higher percentage of breast cancer deaths and has a higher rate of recurrence. This form of breast cancer is twice as likely to occur in African-American women, and approximately 70% to 80% of the breast tumors that occur in women with mutations in the BRCA1 genes are triple-negative breast cancer.


“This vaccine approach represents a potential new way to control breast cancer,” said Vincent Tuohy, Ph.D., the primary inventor of the vaccine and staff immunologist at Cleveland Clinic’s Lerner Research Institute. “The long-term objective of this research is to determine if this vaccine can prevent breast cancer before it occurs, particularly the more aggressive forms of this disease that predominate in high-risk women.” Dr. Tuohy is named as inventor on the technology, which Cleveland Clinic exclusively licensed to Anixa Biosciences, Inc. He will receive a portion of commercialization revenues received by Cleveland Clinic for this technology and also holds personal equity in the company.


The investigational vaccine targets a breast-specific lactation protein, α-lactalbumin, which is no longer found post-lactation in normal, aging tissues but is present in the majority of triple-negative breast cancers. Activating the immune system against this “retired” protein provides pre-emptive immune protection against emerging breast tumors that express α-lactalbumin. The vaccine also contains an adjuvant that activates an innate immune response that allows the immune system to mount a response against emerging tumors to prevent them from growing.


The study is based on pre-clinical research led by Dr. Tuohy that showed that activating the immune system against the α-lactalbumin protein was safe and effective in preventing breast tumors in mice. The research also found that a single vaccination could prevent breast tumors from occurring in mouse models, while also inhibiting the growth of already existing breast tumors. The research, published in Nature Medicine, was funded in part by philanthropic gifts from more than 20,000 people over the last 12 years.
 
Funded by the U.S. Department of Defense, the new study at Cleveland Clinic will include 18 to 24 patients who have completed treatment for early-stage triple-negative breast cancer within the past three years and are currently tumor-free but at high risk for recurrence. During the course of the study, participants will receive three vaccinations, each two weeks apart and will be closely monitored for side effects and immune response. The study is estimated to be completed in September 2022.  
 
Researchers anticipate that a subsequent trial will involve healthy, cancer-free women at high risk for developing breast cancer who have decided to undergo voluntary bilateral mastectomy to lower their risk. Typically, those women carry mutations in either the BRCA1 or BRCA2 gene and are therefore at risk of developing triple-negative breast cancer or have high familial risk for any form of breast cancer.


“This vaccine strategy has the potential to be applied to other tumor types,” added Dr. Tuohy. “Our translational research program focuses on developing vaccines that prevent diseases we confront with age, like breast, ovarian and endometrial cancers. If successful, these vaccines have the potential to transform the way we control adult-onset cancers and enhance life expectancy in a manner similar to the impact that the childhood vaccination program has had.”
 

 


Posted by : DubaiPRNetwork.com Editorial Team
Viewed 8400 times
PR Category : Healthcare & Medicine
Posted on : Wednesday, October 27, 2021  10:51:00 AM UAE local time (GMT+4)
Replication or redistribution in whole or in part is expressly prohibited without the prior written consent of DubaiPRNetwork.com.
Previous Story : Dubai Health Authority Discusses Early Detection of Breast C...
Next Story : Emirates Health Services: Al Qassimi Women's & Children's Ho...
Email this article Print this article

Share this article with your friends and followers
NewsVine
Back to Section Home

Related Stories



 
 
Most Viewed Press Release posted in the last 7 days
Records to Bounce, Flip and Soar for Guinness World Records Day 2021 [8430-Views]
New Ninjamas Nighttime Bedwetting Underwear Helps Kids To Conquer The Night [6982-Views]
The Perfect Autumn Look by essence [4891-Views]
LG Honored With 24 Awards for Innovation Ahead of CES 2022 [4887-Views]
Foreo Festive Gifts for the Well-Groomed Gentleman [4793-Views]
Festive FOREO Gifts for Skincare Gurus this Holiday [4084-Views]
SolarWinds Expands International Leadership Team in EMEA Market [3530-Views]
Line-up for 2022 Emirates Airline Festival of Literature Dazzles With the Creators of Stor... [3460-Views]
Go Green this Black Friday Cathay Pacific Offers Complimentary Carbon Offset [3382-Views]
4 FOREO Products That Will Completely Transform Your Skincare Routine [3300-Views]
Rado Winter Season-Feel The Moment [3296-Views]
Air Tanzania Announces Order for Boeing Freighter and Passenger Jets [3284-Views]
ASTRONEF is a New mechanical Masterpiece Presented by Ateliers Louis Moinet [3038-Views]
Symbolism and Style Defines Tanishq's Exclusive Year of the Fiftieth Collection [3013-Views]
UD Trucks Launches the new Euro 5 Range in the Region and Upgrades its Existing Quester & ... [2890-Views]
The Kia Concept EV9 Kia's All-Electric SUV Concept takes Center Stage at AutoMobility LA [2854-Views]
QNET Reinforces its Commitment to Sustainability with Global Reforestation Initiative [2837-Views]
Liverpool FC Retail Partner Seventy-8 Arranges for UAE Fans to Meet Jose Enrique at Its Ne... [2833-Views]
Comlux Launches New Hangar Project at Mohammed bin Rashid Aerospace Hub [2808-Views]
du Showcases 5G Controlled Robot Over Private 5G SA Network Leveraging AWS and Athonet Tec... [2767-Views]
CS Events to help Disrupt the $1.13 Trillion Events Industry by Deploying Technology and B... [2731-Views]
Celebrate UAE National Day with FreshToHome's Special Bouquets [2726-Views]
Celebrate the UAE This Year of the 50th With Mister Baker [2644-Views]
Channelling Power of the Mind and Body is the Key to Success, say Mindvalley Experts at Sh... [2608-Views]
Pandora and World-Renowned Author, Nadia Owusu, Release a Collection of Festive Stories to... [2587-Views]
 
RSS Facebook Twitter LinkedDin DubaiPRNetwork.com on Instagram
 
Top Sections
 
Top Stories